13F Holdings
中文EN

VIVS VivoSim Labs, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1497253 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.6%
TTM net income YoY-417.8%
TTM EPS YoY-768.6%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,897.8%
Net margin-7,605.9%
FCF margin-7,618.5%
EBITDA margin-8,771.9%

Returns

ROE-143.5%
ROA-104.7%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.50x
Interest coverage-1,001.00x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue63.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$131,000$144,000$109,000$370,000$1.50M
Cost of revenue$0$5,000———
Gross profit$131,000$139,000———
R&D expense$4.19M$5.03M$5.50M$8.88M$3.32M
SG&A expense$7.43M$7.73M$9.70M$9.22M$9.66M
Operating income-$11.49M-$12.62M-$15.09M-$17.73M-$11.48M
Interest expense$12,000$10,000———
Pretax income-$13.84M-$2.49M———
Income tax$2,000$2,000$2,000$2,000$2,000
Net income-$13.84M-$2.49M-$14.67M-$17.26M-$11.45M
EBITDA-$11.27M-$12.35M-$14.81M-$17.44M-$11.34M
EPS (basic)-5.35-1.70-19.25-1.98-1.32
EPS (diluted)-5.35-1.70-19.25-1.98-1.32
Weighted avg. shares (diluted)2.59M1.46M762,0768.71M8.70M
Balance sheet
Cash & equivalents$5.02M$11.31M$2.90M$15.30M$28.68M
Short-term investments————$0
Receivables$32,000$30,000$33,000$152,000$0
Inventory$0$0$297,000$0—
Current assets$6.63M$12.13M$3.94M$17.05M$29.53M
PP&E, net$206,000$419,000$669,000$902,000$662,000
Total assets$7.39M$14.65M$6.35M$20.31M$33.30M
Current liabilities$2.79M$3.74M$1.86M$3.67M$1.38M
Total liabilities$8.48M$4.16M$2.75M$4.98M$3.09M
Shareholders' equity-$1.10M$10.49M$3.60M$15.33M$30.21M
Shares outstanding2.89M1.90M839,8148.72M8.71M
Cash flow statement
Operating cash flow-$10.83M-$9.46M-$14.65M-$12.41M-$8.45M
Capital expenditure$0$13,000$42,000$396,000$409,000
Free cash flow-$10.83M-$9.47M-$14.70M-$12.80M-$8.86M
Investing cash flow$94,000$9.03M$816,000-$966,000-$409,000
Financing cash flow$4.45M$8.85M$1.44M$0$205,000
Depreciation & amortization$215,000$266,000$280,000$293,000$142,000
Stock-based compensation$303,000$532,000$1.51M$2.38M$2.26M
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.